drugset / Trial / NCT00277017

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

NCT00277017

Phase 1/2 Completed 15 enrolled New Mexico Cancer Research Alliance
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment. We also wish to see if the addition of Thalidomide will increase the effectiveness of the already established treatment regimen.

Timeline

Start
2000-09
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 1200 mg Oral
Background Interferon-α Protein / enzyme biologic Subcutaneous
Background aldesleukin Protein / enzyme biologic Intravenous
Background fluorouracil Small molecule Intravenous

Indications